vTv Therapeutics Inc (VTVT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, vTv Therapeutics Inc (VTVT) has a cash flow conversion efficiency ratio of 0.102x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($9.15 Million) by net assets ($89.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See vTv Therapeutics Inc (VTVT) liquidity interval to measure how many days the company can operate on defensive assets alone.
vTv Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how vTv Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
vTv Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of vTv Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Servotronics Inc
NYSE MKT:SVT
|
-0.067x |
|
Hansae Yes24
KO:016450
|
0.105x |
|
Sangoma Technologies Corp
TO:STC
|
0.046x |
|
D&D Platform Reit Co Ltd
KO:377190
|
N/A |
|
Vardhman Holdings Limited
NSE:VHL
|
0.000x |
|
Torimbia Socimi S.A.
MC:YTRM
|
0.191x |
|
MCOT Public Company Limited
BK:MCOT
|
0.043x |
|
Shanghai Huayi Group Corp Ltd B
SHG:900909
|
-0.074x |
Annual Cash Flow Conversion Efficiency for vTv Therapeutics Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of vTv Therapeutics Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see how much is vTv Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $64.44 Million | $-25.25 Million | -0.392x | +77.85% |
| 2024-12-31 | $14.30 Million | $-25.31 Million | -1.770x | -272.03% |
| 2023-12-31 | $-18.55 Million | $-19.08 Million | 1.029x | +139.40% |
| 2022-12-31 | $5.84 Million | $-15.25 Million | -2.611x | -105.85% |
| 2021-12-31 | $15.22 Million | $-19.31 Million | -1.268x | +73.27% |
| 2020-12-31 | $3.79 Million | $-18.00 Million | -4.746x | -282.25% |
| 2019-12-31 | $-8.84 Million | $-23.02 Million | 2.604x | +703.31% |
| 2018-12-31 | $-82.85 Million | $-26.86 Million | 0.324x | +9.88% |
| 2017-12-31 | $-151.05 Million | $-44.56 Million | 0.295x | -44.35% |
| 2016-12-31 | $-90.94 Million | $-48.21 Million | 0.530x | +11.87% |
| 2015-12-31 | $-77.97 Million | $-36.95 Million | 0.474x | +667.92% |
| 2014-12-31 | $-498.81 Million | $-30.78 Million | 0.062x | -55.04% |
| 2013-12-31 | $-303.73 Million | $-41.68 Million | 0.137x | -- |
About vTv Therapeutics Inc
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company… Read more